文献速递功能神经外科

台湾帕金森病丘脑底核脑深部电刺激的成本效果分析

Cost-Effectiveness Analysis of Deep Brain Stimulation for Parkinson Disease in Taiwan.
PubMed 文献 · World Neurosurg · 2020-03-05

本研究基于社会视角构建马尔可夫决策模型,比较丘脑底核脑深部电刺激(STN-DBS)与药物治疗帕金森病的成本效果。结果显示STN-DBS组在3年和10年随访时的生命年增益(LYG)和质量调整生命年(QALY)均高于药物组,增量成本效果比随随访时间延长而降低,根据台湾当前国内生产总值,STN-DBS在LYG和QALY增益方面更具成本效果。

要点

  • STN-DBS组3年LYG为2.937年,药物组为2.632年;10年分别为7.417年和5.971年。
  • STN-DBS组3年QALY为1.739,药物组为1.220;10年分别为4.189和2.88。
  • STN-DBS相较药物的增量成本效果比:3年每LYG 147,065美元、每QALY 123,436美元;10年每LYG 36,833美元、每QALY 69,033美元。

核心结论

  • 根据台湾当前国内生产总值,STN-DBS在生命年增益和质量调整生命年增益方面比药物治疗更具成本效果。

研究设计与样本

  • 基于社会视角构建马尔可夫决策模型,使用Hoehn和Yahr量表及统一帕金森病评定量表运动评分进行多分类逻辑回归模型,并采用马尔可夫链蒙特卡洛模拟启动概率成本效果分析。

主要发现

  • STN-DBS组与药物组3年随访的生命年增益分别为2.937年和2.632年,10年随访分别为7.417年和5.971年。
  • STN-DBS组与药物组3年随访的质量调整生命年分别为1.739和1.220,10年随访分别为4.189和2.88。
  • STN-DBS相较药物的增量成本效果比在3年随访为每生命年增益147,065美元和每质量调整生命年增益123,436美元,10年随访分别为每生命年增益36,833美元和每质量调整生命年增益69,033美元。
  • 当3年支付意愿为每生命年增益150,000美元且每质量调整生命年增益超过90,000美元时,STN-DBS为最优策略;当10年支付意愿为每生命年增益超过38,000美元且每质量调整生命年增益超过41,000美元时,STN-DBS为最优策略。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Deep brain stimulation of the subthalamic nucleus (STN-DBS) is an effective therapy for Parkinson disease (PD). However, cost-effectiveness analysis is required because most patients are older adults and decision makers must therefore consider whether the long-term effectiveness outweighs the initial cost. METHODS: A Markov decision model was constructed on the basis of a societal perspective. The Hoehn and Yahr scale and Unified PD Rating Scale motor score were used in the polytomous logistic regression model. Markov Chain Monte Carlo simulation was used to initiate the probabilistic cost-effectiveness analysis. RESULTS: The life-year gained (LYG) in the STN-DBS group and medication group was, respectively, 2.937 and 2.632 years at the 3-year follow-up and 7.417 and 5.971 years at the 10-year follow-up. The quality-adjusted life-year (QALY) gained in the STN-DBS and medication groups was, respectively, 1.739 and 1.220 at the 3-year follow-up and 4.189 and 2.88 at the 10-year follow-up. The incremental cost-effectiveness ratio of STN-DBS compared with medication was $147,065 per LYG and $123,436 per QALY gained at the 3-year follow-up and $36,833 and $69,033 at the 10-year follow-up, respectively. STN-DBS is an optimal strategy when the willingness to pay is $150,000 per LYG and over $90,000 per QALY gained in 3 years and when the willingness to pay is over $38,000 per LYG and over $41,000 per QALY gained in 10 years. CONCLUSIONS: This study provided data comparing STN-DBS and medical treatment for PD with respect to LYG and QALY gained. STN-DBS was more cost-effective in terms of LYG and QALY gained according to the current gross domestic product of Taiwan.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Fann JC, Chang KC, Yen AM, et al. Cost-Effectiveness Analysis of Deep Brain Stimulation for Parkinson Disease in Taiwan. World Neurosurg. 2020. PMID: 32147563. doi:10.1016/j.wneu.2020.02.150

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。